On May 16, 2024 MAIA Biotechnology, Inc., (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, reported that an abstract about its Phase 2 THIO-101 clinical trial named "A phase 2, multicenter, open-label, dose-optimization study evaluating telomere-targeting agent THIO sequenced with cemiplimab in patients with advanced NSCLC: Updated results" was accepted for poster presentation at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) 2024 Annual Meeting, to take place May 31-June 4, 2024, in Chicago, Illinois (Press release, MAIA Biotechnology, MAY 16, 2024, View Source [SID1234643417]). The poster is scheduled for presentation on June 3, 2024, from 1:30pm to 4:30pm CST.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are proud to accept ASCO (Free ASCO Whitepaper)’s invitation to present at its 2024 Annual Meeting, the most significant gathering of oncology professionals worldwide," said Vlad Vitoc, M.D., MAIA’s Chairman and Chief Executive Officer. "We look forward to revealing the newest efficacy results from THIO-101 and discussing our pioneering telomere targeting science underlying THIO, the first and only cancer treatment of its kind in clinical development."
MAIA’s abstract will be available online at the ASCO (Free ASCO Whitepaper) Annual Meeting 2024 website during the week prior to the conference start date, and the poster will be published on maiabiotech.com on the day of the presentation, June 3, 2024.
The 2024 ASCO (Free ASCO Whitepaper) Annual Meeting will feature more than 200 sessions and 5,000 posters complementing the theme, "The Art and Science of Cancer Care: From Comfort to Cure."